Clincosm LogoSign in Get a demo

Postmenopausal Osteoporosis

Showing 1 - 25 of 98
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Postmenopausal Osteoporosis Trial (Romosozumab)

Not yet recruiting
  • Postmenopausal Osteoporosis
  • (no location specified)
Oct 16, 2023

Low Bone Mineral Density, Postmenopausal Osteoporosis Trial in China (Eldecalcitol capsules, Calcitriol capsules)

Not yet recruiting
  • Low Bone Mineral Density
  • Postmenopausal Osteoporosis
  • Eldecalcitol capsules
  • Calcitriol capsules
  • Changsha, China
  • +20 more
Jun 5, 2023

Postmenopausal Osteoporosis Trial in Cairo (device, behavioral, dietary supplement)

Not yet recruiting
  • Postmenopausal Osteoporosis
  • Ultraviolet Radiation
  • +2 more
  • Cairo, Egypt
    Kasr Alainy medical school
Dec 6, 2022

Postmenopausal Osteoporosis Trial in Beijing (Minodronate, Alendronate)

Not yet recruiting
  • Postmenopausal Osteoporosis
  • Beijing, Beijing, China
    Peking University Third Hospital
Dec 8, 2022

Postmenopausal Osteoporosis Trial in Seoul (Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination)

Not yet recruiting
  • Postmenopausal Osteoporosis
  • Risedronate Sodium 35 MG [Actonel]
  • Calcium Vitamin D combination
  • Seoul, Seodaemun-gu, Korea, Republic of
    Severance Hospital
Nov 29, 2022

Postmenopausal Osteoporosis Trial in Worldwide (Romozosumab, Teriparatide)

Completed
Has Results
  • Postmenopausal Osteoporosis
  • Gainesville, Georgia
  • +49 more
Nov 4, 2022

Osteopenia, Osteoporosis, Postmenopausal Osteoporosis Trial in Birmingham (Exercise training)

Not yet recruiting
  • Osteopenia
  • +3 more
  • Exercise training
  • Birmingham, Alabama
    University of Alabama at Birmingham
Nov 16, 2022

Alendronate inWeekly Effervescent Tablet Formulation Following

Recruiting
  • Postmenopausal Osteoporosis
  • Binosto 70Mg Effervescent Tablet
  • Athens, Attiki, Greece
    251 Hellenic Air Force & VA General Hospital
Nov 6, 2022

Low Bone Mineral Density, Postmenopausal Osteoporosis Trial (Placebo to Romosozumab, Alendronate, Teriparatide)

Completed
Has Results
  • Low Bone Mineral Density
  • Postmenopausal Osteoporosis
  • Placebo to Romosozumab
  • +6 more
  • (no location specified)
Sep 9, 2022

Postmenopausal Osteoporosis Trial in Worldwide (FKS518, US-licensed Prolia)

Active, not recruiting
  • Postmenopausal Osteoporosis
  • Sofia, Sofia City, Bulgaria
  • +75 more
Aug 29, 2022

Postmenopausal Osteoporosis Trial in Uherské Hradište (ENZ215, Prolia)

Recruiting
  • Postmenopausal Osteoporosis
  • ENZ215
  • Prolia
  • Uherské Hradiště, Czechia
    MEDICAL PLUS s.r.o.
Jul 30, 2022

Postmenopausal Osteoporosis Trial in Boston (Teriparatide, Denosumab)

Completed
  • Postmenopausal Osteoporosis
  • Boston, Massachusetts
    Massachusetts General Hospital
Jul 28, 2022

Postmenopausal Osteoporosis Trial in Changchun (JMT103, Denosumab, Placebo)

Recruiting
  • Postmenopausal Osteoporosis
  • Changchun, Jilin, China
    The Second Hospital of Jilin University
Jul 14, 2022

Postmenopausal Osteoporosis Trial in Boston (Romosozumab, Denosumab)

Recruiting
  • Postmenopausal Osteoporosis
  • Boston, Massachusetts
    Massachusetts General Hospital
Jul 14, 2022

Surveillance of EDIROL in Postmenopausal Osteoporosis

Not yet recruiting
  • Postmenopausal Osteoporosis
  • Eldecalcitol soft capsules
  • Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Jun 21, 2022

Postmenopausal Osteoporosis, Postmenopausal Osteopenia Trial in Rawalpindi (High Intensity Exercises, General Exercises)

Completed
  • Postmenopausal Osteoporosis
  • Postmenopausal Osteopenia
  • High Intensity Exercises
  • General Exercises
  • Rawalpindi, Punjab, Pakistan
  • +1 more
Jun 17, 2022

Cross -Cultural Validation of ECOS-16 Questionnaire in Urdu

Completed
  • Postmenopausal Osteopenia
  • +4 more
    • Lahore, Punjab, Pakistan
      Saima Riaz
    Jun 15, 2022

    Postmenopausal Osteoporosis Trial in Beijing (CMAB807 Injection, Prolia®)

    Recruiting
    • Postmenopausal Osteoporosis
    • Beijing, Beijing, China
      Peking Union Medical College Hosptial
    Jun 14, 2022

    Postmenopausal Osteoporosis, Postmenopause, Hyperparathyroidism, Secondary Trial in Mexico City (Cholecalciferol)

    Completed
    • Postmenopausal Osteoporosis
    • +4 more
    • Mexico City, Mexico
      Peri-postmenopause and bone metabolism clinic. Regional Hospital
    Apr 30, 2022

    Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism Trial in Mexico City (Risedronate, Vitamin D)

    Completed
    • Postmenopausal Osteoporosis
    • +2 more
    • Mexico City, Mexico
      Peri-postmenopause and bone metabolism clinic. Regional Hospital
    Apr 20, 2022

    Postmenopausal Osteoporosis Trial in University Park (Dried Plum, Calcium supplement, Vitamin D supplement)

    Active, not recruiting
    • Postmenopausal Osteoporosis
    • Dried Plum
    • +2 more
    • University Park, Pennsylvania
      Women's Health and Exercise Laboratories, The Pennsylvania State
    Mar 31, 2022

    Postmenopausal Osteoporosis Trial in Worldwide (RGB-14-P, Prolia®)

    Recruiting
    • Postmenopausal Osteoporosis
    • Miami Lakes, Florida
    • +57 more
    Feb 22, 2022

    Postmenopausal Osteoporosis Trial in Worldwide (abaloparatide solid microstructured transdermal system, abaloparatide-SC)

    Completed
    • Postmenopausal Osteoporosis
    • abaloparatide solid microstructured transdermal system
    • abaloparatide-SC
    • Birmingham, Alabama
    • +96 more
    Jan 5, 2022

    Postmenopausal Osteoporosis Trial in Poland (SB16 (Proposed Denosumab Biosimilar), Prolia® (Denosumab))

    Active, not recruiting
    • Postmenopausal Osteoporosis
    • SB16 (Proposed Denosumab Biosimilar)
    • Prolia® (Denosumab)
    • Kraków, Poland
    • +4 more
    Oct 13, 2021

    Postmenopausal Osteoporosis, Diabetes Type 2 Trial in Vienna (Prolia, 60 Mg/mL Subcutaneous Solution, Teriparatide)

    Active, not recruiting
    • Postmenopausal Osteoporosis
    • Diabetes Type 2
    • Vienna, Austria
      Medical University Vienna; St. Vincent Hospital
    Oct 2, 2021